Related Experiment Video

Updated: Sep 20, 2026

Isolation, Characterization, and Proteomic Analysis of Plasma-Derived Extracellular Vesicles for Cardiovascular Biomarker Discovery
05:30

Isolation, Characterization, and Proteomic Analysis of Plasma-Derived Extracellular Vesicles for Cardiovascular Biomarker Discovery

Published on: January 31, 2025

Plasma vitronectin levels in patients with coronary atherosclerosis are increased and correlate with extent of

Hakan Ekmekci1, Huseyin Sonmez, Ozlem B Ekmekci

  • 1Department of Biochemistry, Istanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey. hakekmekci@yahoo.com

Journal of Thrombosis and Thrombolysis
|August 13, 2003
PubMed

Insights

Plasma vitronectin levels are significantly elevated in patients with coronary artery disease (CAD). Higher vitronectin may indicate its role in CAD development or progression.

Area of Science:

  • Biochemistry
  • Cardiovascular Medicine
  • Hematology

Background:

  • Atherosclerosis involves plaque disruption and acute thrombosis, leading to ischemic syndromes.
  • Vitronectin (VN) is a glycoprotein involved in blood and extracellular matrix functions, including interactions with collagen, plasminogen, and platelet glycoproteins.
  • VN stabilizes plasminogen activation inhibitor-1 (PAI-1), a key fibrinolysis regulator, and may influence thrombus clearance and platelet aggregation at vascular injury sites.

Purpose of the Study:

  • To investigate plasma vitronectin levels in patients diagnosed with Coronary Artery Disease (CAD).
  • To compare plasma vitronectin levels between CAD patients and a control group.
  • To explore potential correlations between vitronectin levels and the severity of CAD.

Main Methods:

  • Plasma vitronectin levels were determined using ELISA (Technoclone).
  • Patients with CAD were categorized into subgroups based on angiography results: no, single, double, and triple vessel disease.
  • Plasma vitronectin levels were measured and compared across these subgroups and with the control group.

Main Results:

  • Plasma vitronectin levels were significantly higher in patients with CAD (125.87 +/- 58.38) compared to the control group (89.47 +/- 25.3).
  • Patients with double (146.03 +/- 71.69) and triple vessel disease (160.81 +/- 57.02) showed significantly higher plasma vitronectin levels than those with no or single vessel disease and the control group.
  • No correlation was observed between vitronectin levels and lipid parameters.

Conclusions:

  • Elevated plasma vitronectin levels are associated with Coronary Artery Disease (CAD).
  • Vitronectin may serve as a potential biomarker for CAD.
  • Increased vitronectin levels could reflect a role in CAD pathogenesis, progression, or act as a compensatory mechanism.
Abstract

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Related Concept Videos

Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...